All In Biotech

NDA 019779 · Harrow Eye

Iopidine

Apraclonidine Hydrochloride · Ophthalmic

Novel

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Dec 31, 1987

Approved uses

2

Original approval plus efficacy supplements

Registered trials

8

4 Phase 3, 2 recruiting

FAERS reports

1

1 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 8, 2026.

INDICATIONS AND USAGE IOPIDINE 1% Ophthalmic Solution is indicated to control or prevent post-surgical elevations in IOP that occur in patients after argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG posterior capsulotomy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 15, 1989 Supplement 4 · Efficacy
  • Dec 31, 1987 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • IOPIDINE · APRACLONIDINE HYDROCHLORIDE EQ 1% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Apraclonidine" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • retinal haemorrhage1
  • retinopathy1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Iopidine (Apraclonidine HCl)

2024 spending

$37K

Beneficiaries

31

48 claims

Per beneficiary

$1,205

$26.80 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$37,350

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 101 on PubMed

Sponsor: Harrow Eye

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.